DrugPatentWatch Database Preview
Drugs in Development Information for DDP-225
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug DDP-225?
DDP-225 is an investigational drug.
There have been 29 clinical trials for DDP-225.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and First Affiliated Hospital of Guangxi Medical University.
Summary for DDP-225
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-10-01) |
| Vendors | 2 |
Recent Clinical Trials for DDP-225
| Title | Sponsor | Phase |
|---|---|---|
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | Henan Cancer Hospital | Phase 2 |
| GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC | Guiyang Medical University | Phase 3 |
Clinical Trial Summary for DDP-225
Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225
US Patents for DDP-225
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
